logo

MNMD

Mind Medicine
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 4
Sell signal 0
stock price surged significantly
consensus rating "Buy"
Upward Gap
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About MNMD

Mind Medicine (Mindmed) Inc.

A clinical stage biopharmaceutical company developing novel products to treat brain health disorders

Pharmaceutical
Invalid Date
04/27/2021
NASDAQ Stock Exchange
74
12-31
Common stock
One World Trade Center, Suite 8500, New York, New York 10007
--
Mind Medicine (MindMed) Inc., incorporated in Canada. They are a clinical-stage neurodrug development company that develops psychedelic-based drug candidates through rigorous scientific and clinical trials. Their mission is to discover, develop and deploy psychedelic-inspired drugs and therapies to treat psychiatry, neurology, addiction, pain, and potentially other disorders such as anxiety, substance abuse and withdrawal, and adult attention deficit disorder.

Company Financials

EPS

MNMD has released its 2024 Q4 earnings. EPS was reported at -0.41, versus the expected -0.28, missing expectations. The chart below visualizes how MNMD has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime